KLF6-expression contributes to hepatic insulin resistance and the progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) and NASH-cirrhosis4. Here, KLF6 is linked to metabolic dysfunction-associated steatotic liver disease.